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Abstract: Offset analgesia (OA) is a pain-modulating mechanism described as a 
disproportionately large decrease in pain intensity evoked by a discrete decrease in stimulus 
temperature.  The role of the opioidergic, serotonergic and noradrenergic systems on OA 
remains unclear. The aim of the present study was to evaluate whether OA is modulated by 
an opioid (oxycodone) and a serotonin and noradrenaline reuptake inhibitor (venlafaxine) in 
terms of psychophysical assessments. 
In this randomised, double-blinded, placebo-controlled cross-over study, 20 healthy male 
participants (mean age: 24.6±2.5 years) received 10 mg oxycodone, 37.5 mg venlafaxine or 
placebo twice daily for five days in three periods. OA was induced by noxious thermal 
stimulation on the forearm at baseline and last day of treatment. A control session of constant 
stimulus intensity was included for comparison. 
OA magnitude was unaffected by oxycodone and venlafaxine (P=0.20 and P=0.90, 
respectively). Oxycodone affected the control paradigm where a decreased rating of pain 
intensity was observed compared to placebo (P=0.001).   
OA could not be modulated by oxycodone or venlafaxine and may be a robust phenomenon 
in healthy volunteers and not suitable for exploring pharmacological mechanisms of 
analgesia in humans. 
 
Keywords: offset analgesia, oxycodone, venlafaxine, pain modulation 
 
The trial was registered at EU Clinical Trials Register (EudraCT number: 2013-000170-30). 
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Modulation in central nervous system pain processing due to nociceptive input plays an 
important role in chronic pain states. Pain is modulated by complex endogenous systems that 
facilitate and inhibit painful stimuli. One pain-modulating mechanism is offset-analgesia 
(OA) which is described as a disproportionately large decrease in pain intensity evoked by a 
discrete decrease in stimulus temperature
1
. OA has been investigated in a variety of different 
experimental set-ups in healthy volunteers to explore the underlying mechanisms
2,3
 and in 
chronic pain patients where OA was found to be abnormal 
4–6
.  
Results from several fMRI studies have demonstrated that the pain-modulating regions of the 
brainstem are activated during assessment of OA in healthy individuals
7–10
. Many of these 
regions, such as the periaqueductal grey, are involved in opioidergic analgesia. Moreover, 
areas consistent with serotonergic and noradrenergic nuclei were activated during assessment 
of OA
8
. Serotonin and noradrenaline reuptake inhibitors (SNRI) like e.g. venlafaxine 
modulate the serotonergic and noradrenergic pathways simultaneously, likely by involvement 
of enhancement of descending pain inhibitory activity. Thus, theoretically, OA may be 
modulated by SNRIs and opioids.  
Pharmacological modulation of OA has been investigated but the magnitude of offset 
analgesia was not altered by tapentadol, morphine, remifentanil, naloxone or ketamine in 
either healthy volunteers or patients 
2–5
. However, methodological challenges, as e.g. few 
pain ratings over time, lack of control paradigm or the use of absolute changes instead of 
relative changes in pain scores, may lead to inconclusive results on the pharmacological 
modulation and the role of the opioidergic, noradrenergic and serotonergic systems on pain 
modulation remains unclear. Due to limitations in previous studies and the heterogeneous 
picture about the suitability of OA in analgesic drug studies, reassessment and detailed 
analysis of the method is warranted. 
A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved. 
It was hypothesized that an opioid (oxycodone) and an SNRI (venlafaxine) would increase 
OA as compared to placebo. To test this hypothesis, the aim of the present study was to 
evaluate the effects of oxycodone and venlafaxine on OA in terms of relative changes in 
psychophysical assessments and compare the effects to a control paradigm.  
Methods 
A double-blinded, randomised placebo-controlled, cross-over study was performed. The 
study was designed and conducted to investigate different mechanisms of oxycodone and 
venlafaxine. Other endpoints have  previously been published
11,12
. The study was approved 
by The North Denmark Region Committee on Health Research Ethics and the Danish 
Medicines Agency (N-20130011 and EudraCT number: 2013-000170-30) and registered at 
EU Clinical Trials Register.  
The study was carried out according to the principles of Good Clinical Practice (GCP) and 
monitored by the GCP unit at Aalborg and Aarhus University Hospitals, Denmark. 
Recommendations of the Helsinki declaration (2013) were followed. Data were collected in 
the research laboratories at Mech-Sense, Department of Gastroenterology, Aalborg 
University Hospital, Denmark, from November 2013 to December 2014. Written informed 
consents were obtained from participants before the study procedures.  
Twenty healthy male participants were randomized to five-day, three-arm treatment with 
oxycodone, venlafaxine or placebo in a double-blinded, randomized sequence, in three 
periods. Each period began on day 1 with baseline OA assessments and ended on day 5 with 
new OA assessment. Between treatments, a washout period of minimum 7 days was inserted. 
Inclusion criteria for the study were: 1) age between 20 and 35 years; 2) ability to read and 
understand Danish; 3) Scandinavian origin; 4) clinical examination ruling out any diseases 
and 5) male.  
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Exclusion criteria were: 1) known allergy towards study medication; 2) participation in other 
studies within two weeks prior to first visit; 3) expected need of medical/surgical treatment 
during the course of the study; 4) history of psychiatric illness; 5) history of persistent or 
recurring pain conditions; 6) history of substance abuse; 7) family history of substance abuse; 
8) use of any analgesic medication within 24 hr prior to and during the study; 9) use of 
prescribed medicine and/or herbal medicine and 10) need to drive motor vehicle within the 
treatment periods. 
 
Study medication 
Oxycodone, venlafaxine and placebo were administered orally as extended release tablets and 
capsules, respectively. The tablets and capsules were further encapsulated and masked so all 
administered capsules looked identical. These capsules were produced and packed by the 
Hospital Pharmacy, Central Denmark Region, Denmark, where a randomization list was 
generated bywww.randomization.com. Participants and study personnel were blinded to 
interventions. 
The dosages for oxycodone were 10 mg extended release, and for venlafaxine the dosages 
were 37.5mg extended release. These are the lowest clinical, therapeutic dosages 
(pro.medicin.dk). A steady-state plasma concentration is reached within 24 hr for oxycodone 
and within 72 hr for venlafaxine treatment. Hence, 4 days of treatment was considered 
appropriate. On study day 1 and day 5, medications were administered once daily (QD), and 
on study day 2-4 twice daily (BID); thus, a total of eight doses were administered.  
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Experimental procedure 
Prior to study enrolment, a screening session was performed to familiarize participants with 
the experimental procedures.  
The contact heat stimulation was induced by using the PATHWAY Pain and Sensory 
Evaluation System (Medoc Ltd, Ramat Yishai, Israel). The standard thermode (contact heat-
evoked potential stimulator) stimulated a surface area of 6.6 cm
2
 using a computer-controlled 
OA stimulus paradigm. The temperature was increased from 35ºC, with 1.5ºC/second to 
determine individual pain tolerance thresholds (PTTindividual). The PTT was determined three 
times, and the average temperature was used in the following OA/CS stimulation paradigms.  
The OA paradigm consisted of three contiguous phases (Figure 1): T1) an initial noxious 
stimulus temperature (PTTindividual – 1°C, 5-sec. duration); T2) a 1°C increase to a second 
temperature (PTTindividual, 5-sec. duration), and then T3) a decrease back to the temperature 
used in T1 (PTTindividual – 1 °C, 20-sec. duration). After T3, the temperature decreased back to 
baseline (1.5 ºC/sec.). The control paradigm consisted of a constant stimulus (CS) paradigm 
(PTTindividual - 1°C for 30 sec.). 
During the contact heat stimulation, the participants were asked to evaluate and report the 
pain intensity continuously using Medoc’s computerized scale. The participants were 
instructed to evaluate both innocuous and noxious sensations on a modified visual analogue 
scale (VAS). VAS scores were defined as: 0 = no perception, 1 = vague perception of mild 
sensation, 2 = definite perception of mild sensation, 3 = vague perception of moderate 
sensation, 4 = definite perception of moderate sensation, 5 = the pain detection threshold, 6 = 
mild pain, 7 = moderate pain, 8 = pain of medium intensity, 9 = intense pain and 10 = 
unbearable pain 
13
. 
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The OA and CS paradigms were performed in randomized order. After the OA/CS paradigms 
had been performed at baseline, drugs were administered twice daily for five consecutive 
days. Hereafter, the OA/CS paradigms were repeated.  
 
Statistical analysis 
The results are listed as mean values with standard deviations (SD) unless otherwise 
indicated. Before statistical analyses, the following parameters were calculated for each 
participant: Peak (maximum VAS rating within T2); Nadir (minimum VAS rating within T3); 
∆VAS (decrease in pain ratings that occurred between peak and nadir (Peak – Nadir)) and 
ΔVAScorrected as a measure of OA magnitude (ΔVAS normalized with respect to peak value 
((ΔVAS/peak)*100)) (Fig. 1). 
Before further statistical analysis, average baseline values were calculated, as a mean of three 
single values, for each participant. Data were analysed using repeated measures regression 
with treatment as random effect using the “xtmixed command” in Stata. Sample size 
calculation was based on previous studies in healthy volunteers. However, as no previous 
study has investigated venlafaxine effect on OA, the calculation was an estimate. Stata 12.1 
(Stata Corporation, College Station, Texas, USA) was used in the statistical analysis. P-
values <0.05 were considered significant.  
 
Results 
Twenty opioid-naïve, male participants with mean age of 24.6±2.5 years were included. Due 
to technical issues, baseline values were not assessed during all sessions for two participants. 
In these two cases, the average baseline was calculated based on two measures instead of 
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three. Thus, complete data were available for analysis from all twenty participants. Mean 
PTTindividual used for the OA and CS paradigm was 48.8±1.2°C.  
 
The effect of oxycodone and venlafaxine on OA 
Results on OA endpoints are presented in Table 1. The average magnitude of OA 
(VAScorrected) at baseline was 68.3±19.0%. There were no significant differences in the 
magnitude of OA after treatment with either oxycodone or venlafaxine compared to placebo 
(P=0.20 and P=0.90, respectively). Moreover, no other OA endpoints (Peak, Nadir, VAS) 
were affected by oxycodone or venlafaxine compared to placebo (Peak: P=0.32 and P=0.39; 
Nadir: P=0.23 and 0.81; VAS: P=0.40 and 0.88, respectively).  
 
The effect of oxycodone and venlafaxine on control paradigm 
Results on the control paradigm are presented in Table 1. The average decrease in pain rating 
during the control session at baseline was 29.8±16.8%. This decrease in pain rating was 
unaffected by oxycodone and venlafaxine compared to placebo (P=0.30 and P=0.41, 
respectively). Oxycodone treatment resulted in a reduced peak pain rating (VAS) in the 
control paradigm compared to placebo (-11.4±15.5, P=0.001) whereas no effect of the 
venlafaxine treatment was found (-2.0±12.0, P=0.31). 
Discussion   
In the present study, no modulatory effects of oxycodone and venlafaxine on OA were found, 
and thus involvement of central mechanisms via modulation by opioidergic, serotonergic or 
noradrenergic pathways could not be demonstrated.  
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The brain regions associated with pain perception during OA are known to be rich in opioid 
receptors
14
. Thus, it was hypothesized that modulation of OA is dependent on the opioidergic 
system. This could, however, not be confirmed by results from the present study. Supporting 
this, it has been shown that OA persists despite administration of naloxone
2
. Furthermore, 
results from previous studies indicate that OA was unaltered after administration of the 
opioid agonists morphine, hydromorphone and remifentanil
2,5,15
. Together, these findings 
defy that the opioidergic system is involved in the modulation of OA. Other pharmacological 
agents have also been tested in the OA paradigm. For example, it has been demonstrated that 
ketamine infusion did not affect OA in healthy volunteers or patients
3,5
. Ketamine 
antagonizes the N-methyl-D-aspartate receptors (NMDA) within the spinal cord, 
consequently decreasing ascending input to higher order structures
16
. Thus, it appears that the 
underlying mechanisms of OA are independent on NMDA receptors as well as the 
opioidergic, serotonergic and noradrenergic pathways. However, it cannot be excluded that 
OA is dependent on these pathways as several factors may affect outcomes and lead to 
misleading conclusions. In the OA testing paradigm, different parameters can reveal changes 
in pain sensitivity as well as in the magnitude and duration of OA. ΔVAS, also known as the 
magnitude of OA
2,17,18
, is the test parameter which classically contains information about the 
OA modulation as it comprises information of the peak- and the nadir values. In this study, 
the ΔVAS was normalized (ΔVAScorrected) with respect to peak value in order to circumvent a 
potential artefact arising from variability in peak VAS scores between individuals 
3
. This 
normalized value is probably more robust and suitable to detect subtle pharmacological 
modulations of OA due to reduced variability. Another factor that may affect the outcome is 
the study population. For example, one previous study included a rather small number of 
patients and type I error cannot be excluded
5
. Additionally, the estimated OA effect may be 
affected by adaptation. Thus, a control session with a constant stimulus paradigm was 
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included in the present study, and it was demonstrated that pain ratings decreased 
approximately 30% (VAScorrected) in a constant stimulus paradigm (CS) as an indication of 
adaptation to the stimulation intensity. Heat stimuli have been shown to primarily affect C-
fibres
19
. Peak pain intensity score was reduced in the control paradigm after treatment with 
oxycodone, indicating analgesia on the tonic thermal stimulation due to attenuation of C-fibre 
activated pain by the opioid 
20
.  
In the clinic, venlafaxine does not exert a robust effect on depression until after 2-4 weeks of 
treatment
21
. However,  effects on venlafaxine on the pain system have been observed already 
after a few days
11,22
. Despite this, no analgesic effect of venlafaxine was found in the present 
study indicating that venlafaxine at the current dose does not affect acute C-fibre-activated 
pain. None of the study treatments affected adaptation in the control paradigm, and therefore 
our results suggest that opioidergic, serotonergic and noradrenergic mechanisms are not 
involved in OA or adaptation. The results indicated that adaptation may account for 40% of 
the OA effect (CS ∆VAS=23.9 compared to OA ∆VAS=57.9), indicating the importance of 
including a control paradigm in future studies to distinguish between OA and adaptation. 
Most studies have used thermal stimulus to evoke OA
23
 but one study induced OA with a 
visceral pressure stimulus, indicating that OA is not specific to thermal pain
24
. Since no gold 
standard exists, small differences in protocols are present 
23
 and  more studies are needed for 
further evaluation of OA mechanisms and specificity. 
In previous studies, the classical VAS has been used. The classical VAS is a 10-cm 
continuous line with two extremes as endpoints only evaluating painful sensation going from 
no pain to the most intense pain imaginable
25
. Thus, the nadir cannot be less than zero (no 
pain) and hereby the OA magnitude cannot be influenced by innocuous sensations. In 
contrast, the pain scale used in the present study was a modified VAS, which has been tested 
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for reliability and robustness in a variety of pharmacological experiments in healthy 
participants and in different patient groups
13
 and also previously used in the OA testing 
paradigm
26
. This version included both the innocuous and noxious sensory ranges. However, 
despite a wider dynamic range, the present study could not demonstrate any treatment effects 
on OA.  
As this study was conducted in healthy volunteers, it cannot be excluded that the opioidergic 
system and the serotonergic and noradrenergic systems are involved in OA in patients with 
chronic pain, as different pharmacological effects may be found in the sensitized pain 
system
27
 and there are indications for decreased OA in neuropathic pain patients
5,23
. Studies 
have also investigated if offset analgesia was disrupted during sensitized states in healthy 
volunteers. The magnitude of OA remained intact after both capsaicin-heat and heat only 
sensitization in zones of both primary and secondary mechanical allodynia
17
. Moreover, it 
was recently demonstrated that OA is not modulated by exercise
28
. One study found that 
conditioned pain modulation (CPM) may modulate OA non-pharmacologically as an additive 
effect of CPM and OA on pain inhibition was found in healthy males 
29
. However, study 
limitations as for example group-averaged pain ratings obtained from 6 predefined time 
points, and OA magnitude calculated in reference to constant  (at T3 time point) and not to 
corrected to T2 temperature may have affected results and further studies are warranted to 
confirm this relationship. 
 
In conclusion, the present study in a homogeneous group of healthy volunteers, using the 
ΔVAScorrected, a VAS with a wider dynamic range and a control paradigm for evaluation of 
adaption, found no effect of oxycodone or venlafaxine on OA. As it appears that 
pharmacological agents do not affect the part of the pain modulatory behaviour as revealed 
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by OA, OA may be a robust phenomenon in healthy volunteers and unsuitable for exploring 
pharmacological mechanisms of analgesia in healthy volunteers. 
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Figure legends: 
 
Figure 1. Graph depicting the offset analgesia and control stimulus paradigms 
The offset analgesia (OA) paradigm (black, dashed line) consists of three phases. Initially, the 
temperature increases and stabilizes to a plateau previously defined (T1). Then, the 
temperature increases 1°C (T2) whereafter temperature decreases to T1 level (T3). The 
control stimulus (CS) paradigm (grey line) is single phasic where the temperature increases 
and stabilizes to a plateau, which is kept until the end of stimulation. The corresponding pain 
intensities for OA (red, dashed line) and CS (blue line) are illustrated. Also depicted 
(triangles) are Peak (maximum VAS rating within T2); Nadir (minimum VAS rating within 
T3) and ∆VAS (decrease in pain ratings that occurred between peak and nadir (Peak – 
Nadir)). ΔVAScorrected is not depicted but used in the analysis as a measure of OA magnitude 
((ΔVAS/Peak)*100 )..   
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Table 1. Pain perception endpoints during OA and CS paradigms.  
 
 OA paradigm 
 Average baseline Placebo Oxycodone Venlafaxine 
Peak 84.4 (9.4) 84.2 (10.3) 81.7 (13.8) 82.0 (12.3) 
Nadir 26.5 (16.0) 33.4 (25.0) 26.2 (22.8) 32.0 (20.7) 
VAS 57.9 (17.8) 50.9 (25.4) 55.6 (21.7) 50.0 (21.4) 
VAScorrected 68.3% (19.0) 60.3% (29.4) 69.3% (25.5) 61.2% (26.0) 
 CS paradigm 
 Average baseline Placebo Oxycodone Venlafaxine 
Peak 79.2 (9.5) 81.2 (11.8) 67.8 (15.7)* 77.2 (14.1) 
Nadir 55.2 (14.5) 56.2 (19.6) 51.7 (19.1) 49.4 (25.5) 
VAS 23.9 (15.3) 25.0 (21.3) 16.1 (18.6) 27.8 (24.0) 
VAScorrected 29.8% (16.8) 30.1% (23.3) 22.2 % (24.5) 36.4% (29.3) 
 
P <0.05 considered significant: * significant difference between active treatment and placebo. P-
value. Peak (maximum VAS rating within T2); Nadir (minimum VAS rating within T3); ∆VAS (decrease 
in pain ratings that occurred between peak and nadir (Peak – Nadir)) and ΔVAScorrected as a measure 
of OA magnitude (ΔVAS normalized with respect to peak value ((ΔVAS/peak)*100 )). 
 
